Learning Objectives:
- Review current initial therapy for patients with CLL who are <65 years old
- Review the role of ibrutinib in CLL treatment currently
- Discuss the future of ibrutinib as a possible first line therapy for patients <65 years old
Learning Objectives:
- Understand the prognostic implication of cell of origin in DLBCL and identify emerging therapies for specific subtypes by cell of origin classification
- Define double-expressing lymphoma and its interaction with cell of origin
- Understand whom to test for “double-hit” lymphoma and current treatment recommendations
Session date:
09/18/2017 - 12:00pm to 1:00pm CDT
Location:
University of Chicago Medicine
5841 South Maryland Avenue
MC2115, Conference Room E-215
Chicago, IL
60637
United States
See map: Google Maps
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Brian Hess, MD and Michael Leukam, MD